Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Preparation and Characterization of a New Alternative Formulation of Sodium p-aminosalicylate

Author(s):  Hergert Lisandro Y, Sperandeo Norma R, Allemandi Daniel A, Mazzieri Maria R

Issue:  Jul/Aug 2011 - Volume 15, Number 4
View All Articles in Issue

Page(s):  344-349

Preparation and Characterization of a New Alternative Formulation of Sodium p-aminosalicylate Page 1
Preparation and Characterization of a New Alternative Formulation of Sodium p-aminosalicylate Page 2
Preparation and Characterization of a New Alternative Formulation of Sodium p-aminosalicylate Page 3
Preparation and Characterization of a New Alternative Formulation of Sodium p-aminosalicylate Page 4
Preparation and Characterization of a New Alternative Formulation of Sodium p-aminosalicylate Page 5
Preparation and Characterization of a New Alternative Formulation of Sodium p-aminosalicylate Page 6

Download in electronic PDF format for $75

Abstract:  Sodium p-aminosalicylate is an orphan drug used in patients affected with multidrug-resistant tuberculosis. In this article, the preparation and characterization of a new alternative formulation of p-aminosalicylate is described. It consists of a powder for extemporaneous reconstitution, p-aminosaliyilate–extemporaneous, to be orally administered in solution. It is finally packaged in a tightly closed, light-resistant glass container as a unitary dose. In order to promote accessibility to multidrug-resistant tuberculosis treatment, the formulation is low cost and simple to manufacture, being compounded with only four ingredients. To improve patient compliance and treatment adherence, the unpleasant taste of p-aminosalicylate was masked as p-aminosalicylate–extemporaneous, which is easier to drink. The p-aminosalicylate–extemporaneous was characterized in relation to its content uniformity, time of blending, powder bulk properties (flowability), and stability. The proposed alternative formulation remained stable in its final containers for 3 months, as demonstrated by analytical assays and flowability properties.

Related Keywords: Lisandro Y. Hergert, RPh, PhD, Norma R. Sperandeo, PhD, Daniel A. Allemandi, RPh, PhD, Maria R. Marrieri, PhD, sodium p-aminosalicylate, multidrug-resistant tuberculosis, formulation, drug resistance, patient compliance, extemporaneous reconstitution, bulk powder, stability, packaging, Argentina

Related Categories: FORMULATIONS, PACKAGING, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, INFECTIOUS DISEASE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Preparation and Characterization of a New Alternative Formulation of Sodium p-aminosalicylate
Hergert Lisandro Y
, Sperandeo Norma R, Allemandi Daniel A, Mazzieri Maria R
Jul/Aug 2011
Pg. 344-349

Validation of Ultraviolet-visible and High-performance Liquid Chromatographic Methods for the Determination of Sodium p-Aminosalicylate and m-Aminophenol in a New Pharmaceutical Formulation
Hergert Lisandro Y
, Ravetti Soledad, Mazzieri Maria R
Jan/Feb 2016
Pg. 63-70

Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh
Allen Loyd V Jr
Nov/Dec 2003
Pg. 449-450

Stability of Ampicillin Sodium, Nafcillin Sodium, and Oxacillin Sodium in AutoDose Infusion System Bags
Zhang Yanping
, Trissel Lawrence A
May/Jun 2002
Pg. 226-229

Sodium Nitroprusside and Sodium Thiosulfate Intravenous Admixture
Allen Loyd V Jr
Jan/Feb 2011
Pg. 71

Alkalizing Agents, Featured Excipient:
Allen Loyd V Jr
Sep/Oct 1999
Pg. 404-405

Basics of Compounding for Cold Sores or Fever Blisters
Allen Loyd V Jr
May/Jun 2004
Pg. 206-209

Stability of Piperacillin Sodium After Reconstitution in 0.9% Sodium Chloride Injection and Storage in Polypropylene Syringes for Pediatric Use
Gupta Vishnu D
, Ling Jie
May/Jun 2001
Pg. 230-231

Topical Use of Sodium Cromoglicate (Cromolyn Sodium) to Treat Atopic Dermatitis and Other Skin Allergies
Zur Eyal
Sep/Oct 2012
Pg. 386-393

Aminohippurate Sodium 250 mg/mL Injection
Allen Loyd V Jr
Mar/Apr 2023
Pg. 142

PostScription: Case Reports and Formulations, George Roentsch, RPh.
Roentsch George
Mar/Apr 2001
Pg. 160

Physical and Chemical Stability of Trepostinil Sodium Injection Packaged in Plastic Syringe Pump Reservoirs.
Xu Quanyun A
, Trissel Lawrence A, Pham Lien
May/Jun 2004
Pg. 228-230

Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration
Ben Michel
, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
Nov/Dec 2007
Pg. 520-524

A Compendium of Compounding Agents and Formulations, Part 6: Additional Preparations for Refractory Dermal-wound Healing
Riepl Mike
Nov/Dec 2022
Pg. 480-488

Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design
Patel Gopesh
, Davis Countaney, Liu Yi, Ip Kendice, Debideen Krystal E, Anderson Stephanie, Byrne Robert, Herr Dylan, Rhoads Melissa Merrell, Caputo Ross, Banov Daniel, Bassani August S
Jan/Feb 2021
Pg. 73-81

Sodium Chloride 0.9% Ointment
Allen Loyd V Jr
Jul/Aug 2008
Pg. 357

Liothyronine Sodium (T3) 5-mcg/0.1-mL Transdermal Cream
Allen Loyd V Jr
Nov/Dec 2008
Pg. 546

Cyclobenzaprine Hydrochloride 0.5% and Diclofenac Sodium 3% in Pluronic Lecithin Organogel
Allen Loyd V Jr
Nov/Dec 2008
Pg. 540

Diclofenac Sodium 1% Topical Gel
Allen Loyd V Jr
May/Jun 2011
Pg. 243

PreScription: The International Academy of Compounding Pharmacists Remembers Evelyn Timmons, RPh, FIACP, and George Roentsch, RPh, FIACP
Karolchyk Scott
Jan/Feb 2012
Pg. 4

View Sample
Return to Top